University of Texas System

The Texas A&m University System

Raimund Johannes Ober

Elizabeth Sally Ward Ober

E Sally Ward

Venkata Siva Charan Devanaboyina

Jeffrey Kang

Ran Li

Wei Sun

Jayakumar Poovassery

Jeffrey Che-Wei Kang

Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. The endolysosomal targeting conjugate includes a targeting component and a cargo component. The targeting component is configured to bind to a cell surface molecule of a target cell and the cargo component includes a cargo molecule. The targeting component and the cargo component may be fused by a covalent bond or associated by a non-covalent bond. The targeting component may bind to the cell surface molecule or the cargo component with higher affinity in the extracellular space than in an endolysosomal compartment of the target cell.

Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells

The present disclosure includes a fusion protein, called a 'Seldeg', including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule at near-neutral pH, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind a target antigen-specific antibody. The present disclosure also includes a method of depleting a target antigen-specific antibody from a patient by administering to the patient a Seldeg having an antigen component configured to specifically bind the target antigen-specific antibody.

Fusion proteins (Seldegs) for selectively depleting antigen-specific antibodies and methods of use thereof

The disclosure provides monoclonal bispecific antibodies targeting HER2 and HER3. The disclosure also provides monospecific tetravalent HER3 antigen binding antibodies. Still further provided by the disclosure are methods of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody provided by the disclosure.

Targeting HER2 and HER3 with bispecific antibodies in cancerous cells

Growing community of inventors

College Station, TX, United States of America

Raimund Johannes Ober